Skip to main content

Table 2 Multivariate analysis of prognostic factors for OS after cerebral relapse (n = 54)

From: Survival, prognostic factors, hospitalization time and clinical performance status after first cerebral relapse or progression in 54 patients with primary CNS lymphoma not eligible for high dose chemotherapy: a retrospective analysis

Variables

HR

95% CI

p-value

Age (continuous)

1.071

1.024–1.121

0.003

KPS (continuous)

0.992

0.965–1.020

0.571

Gender (male vs. female)

0.588

0.277–1.246

0.166

Charlson comorbidity score 0 vs. ≥ 1

0.889

0.390–2.025

0.779

No involvement of DBS vs. involvement of DBS

0.756

0.386–1.479

0.413

Refractory vs. relapse

2.152

0.909–5.094

0.081

Asymptomatic vs. symptomatic

0.426

0.189–0.960

0.040

Time in remission < vs. ≥ 12 months

0.773

0.313–1.906

0.576

Any other treatment vs. WBRT/focal radiotherapy

2.239

0.450–11.139

0.325

Any other treatment vs. HD-MTX-based therapy

3.720

0.548–25.275

0.179

Any other treatment vs. TMZ monotherapy/TMZ + rituximab

1.269

0.253–6.372

0.772

Best supportive care vs. any salvage treatment

6.018

0.968–37.406

0.054

  1. Abbreviations: DBS = deep brain structures, HD-MTX = high dose methotrexate, HR = hazard ratio, ICV = intracerebroventricular, KPS = Karnofsky performance score, LDH = lactate dehydrogenase, TMZ = temozolomide, WBRT = whole brain radiotherapy